CAMPTOSAR 20 MG
IRINOTECAN HYDROCHLORIDE : 20 MG · DIN 02231622 · PFIZER CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is CAMPTOSAR?
CAMPTOSAR 20 MG contains IRINOTECAN HYDROCHLORIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02231622, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 02-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CAMPTOSAR used for?
CAMPTOSAR (irinotecan hydrochloride for injection) is indicated as: a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. a single agent for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-fluorouracil-based therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02231622 |
|---|---|
| Brand name | CAMPTOSAR |
| Generic / active ingredient | IRINOTECAN HYDROCHLORIDE : 20 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 20 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01CE02 IRINOTECAN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 02-Jun-2022 |
| Original market date | 1997-08-27 00:00:00 |
How is it stored and handled?
The infusion solutions, when packaged in low-density polyethylene (LDPE) or polyvinyl chloride (PVC) containers, are physically and chemically stable for up to 28 days at controlled room temperature (15 to 30 °C) or at refrigerated temperatures (2 to 8 °C), if protected from light. If stored at room temperature (15 to 30 °C) but exposed to light, the infusion solutions are physically and chemically stable for 72 hours (3 days). Freezing CAMPTOSAR and admixtures of CAMPTOSAR may result in precipitation of the drug and should be avoided.
How is it supplied?
300 mg in 15 mL of solution
Is IRINOTECAN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by PFIZER CANADA ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01CE02 IRINOTECAN. 8 of 18 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| IRINOTECAN FOR INJECTION | 20 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02312409 |
| IRINOTECAN HYDROCHLORIDE INJECTION | 100 MG / 5 ML | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02501279 |
| IRINOTECAN HYDROCHLORIDE INJECTION | 100 MG / 5 ML | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528800 |
| IRINOTECAN HYDROCHLORIDE INJECTION | 500 MG / 25 ML | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02501295 |
| IRINOTECAN HYDROCHLORIDE INJECTION | 500 MG / 25 ML | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528789 |
| IRINOTECAN HYDROCHLORIDE INJECTION USP | 20 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02258218 |
| IRINOTECAN HYDROCHLORIDE INJECTION USP | 20 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02357585 |
| IRINOTECAN HYDROCHLORIDE INJECTION, USP | 20 MG | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02452421 |
| IRINOTECAN | 20 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02410419 |
| IRINOTECAN HYDROCHLORIDE INJECTION | 20 MG | SOLUTION | TELIP, LLC, A SUBSIDIARY OF TELIGENT, INC. | CANCELLED POST MARKET | DIN 02412187 |
Who else supplies IRINOTECAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IRINOTECAN appears in 137 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.